Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22741156 | 0.99 | ESR1 (0.32) | ESR1ESR2PGRMEN1THRB | |
| SCHEMBL22740595 | 0.96 | ESR1 (0.33) | ESR1ESR2MEN1THRBRECQL | |
| SCHEMBL22740569 | 0.95 | ESR1 (0.33) | ESR1ESR2PGR | |
| SCHEMBL22741145 | 0.91 | ERAP1 (0.33) | ESR1ESR2MEN1THRBRECQL | |
| SCHEMBL22741204 | 0.91 | MAOB (0.33) | ESR1ESR2 | |
| SCHEMBL22742288 | 0.90 | ESR1 (0.32) | ESR1ESR2MEN1THRBRECQL | |
| SCHEMBL22741557 | 0.90 | ESR1 (0.33) | ESR1ESR2MEN1THRBRECQL | |
| SCHEMBL22740598 | 0.88 | ERAP1 (0.32) | MEN1THRBRECQLBLMKMT2A | |
| SCHEMBL22743063 | 0.88 | ERAP1 (0.32) | MEN1THRBRECQLBLMKMT2A | |
| SCHEMBL22741498 | 0.87 | PGR (0.38) | ESR1ESR2PGRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377513-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377513-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE | PIEZO1, TMEM109, LEF1 | ESR1 280/4885ESR2 682/4885PGR 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.